Product nameAnti-WISP3 antibody
See all WISP3 primary antibodies
DescriptionRabbit polyclonal to WISP3
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Macaque monkey
Synthetic peptide corresponding to Human WISP3 aa 300 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
- Recombinant human WISP3 protein (ab50049) can be used as a positive control in WB. This antibody gave a positive signal in Human kidney tissue lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab103263 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 46 kDa (predicted molecular weight: 37 kDa).|
|ICC/IF||Use a concentration of 10 µg/ml.|
FunctionAppears to be required for normal postnatal skeletal growth and cartilage homeostasis.
Tissue specificityPredominant expression in adult kidney and testis and fetal kidney. Weaker expression found in placenta, ovary, prostate and small intestine. Also expressed in skeletally-derived cells such as synoviocytes and articular cartilage chondrocytes.
Involvement in diseaseDefects in WISP3 are the cause of progressive pseudorheumatoid arthropathy of childhood (PPAC) [MIM:208230]. PPAC is an autosomal recessive disorder characterized by stiffness and swelling of joints, motor weakness and joint contractures. Signs and symptoms of the disease develop typically between three and eight years of age. This progressive disease is a primary disorder of articular cartilage with continued cartilage loss and destructive bone changes with aging.
Sequence similaritiesBelongs to the CCN family.
Contains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 1 IGFBP N-terminal domain.
Contains 1 TSP type-1 domain.
- Information by UniProt
- CCN 6 antibody
- CCN family member 6 antibody
- CCN6 antibody
Anti-WISP3 antibody (ab103263) at 1 µg/ml + Human kidney tissue lysate - total protein (ab30203) at 10 µg
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 37 kDa
Observed band size: 46 kDa why is the actual band size different from the predicted?
Additional bands at: 36 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 20 minutes
WISP3 contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
ICC/IF image of ab103263 stained MCF-7 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab103263 at 10µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
ab103263 has not yet been referenced specifically in any publications.